

Setting a New Standard of Care in Advanced Lung Cancer

Saturday, 9 September 2017

13:00 – 14:30

Satellite Symposium
Sponsored by MSD

IFEMA, Feria de Madrid
Valencia Auditorium Hall 4
Madrid, Spain

Chair: Luis Paz-Ares (Spain)

CHAIR

Luis Paz-Ares

Head, Medical Oncology Department
Hospital Universitario 12 de Octubre
Madrid, Spain

FACULTY

Corey Langer

Professor of Medicine
Director of Thoracic Oncology
University of Pennsylvania
Philadelphia, Pennsylvania, USA

Educational Objectives

- Present a critical review of the latest data on immune checkpoint inhibitors for patients with lung cancer, including rationale for treatment and appropriate patient selection based on tumor expression
- Deliver on the efficacy and safety/tolerability profile of pembrolizumab, with appropriate balance
- Educate on the immune-related adverse events associated with treatment of immunotherapies in patients with lung cancer
- Communicate the value of immunotherapy as a monotherapy and as a combination therapy partner for patients with thoracic malignancies

AGENDA

13:00 – 13:05	Welcome and Introduction	Luis Paz-Ares
13:05 – 13:20	Anti-PD-1 in Lung Malignancies: A Critical Look at the Landscape	Luis Paz-Ares
13:20 – 13:35	Optimizing Patient Management • Example Cases	Corey Langer
13:35 – 13:50	Future Directions: Anti-PD-1s in SCLC, Mesothelioma, and Early-Stage Disease	Luis Paz-Ares
13:50 – 14:25	Panel Discussion	Faculty
14:25 – 14:30	Closing Remarks	Luis Paz-Ares